[Antibiotic therapy regimens for mild community-acquired pneumonia in patients with risk factors for ineffective treatment: clinical and economic comparisons].

Autor:	Zaĭtsev AA, Makarevich AM, Kondrat'eva TV, Kalugin VV
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2013; Vol. 85 (12), pp. 41-6.
Abstrakt:	Aim: To evaluate the clinical efficiency, tolerance, and pharmacoeconomic parameters of treatment for mild community-acquired pneumonia (CAP) in patients with risk factors for ineffective treatment with levofloxacin (Glevo) versus original levofloxacin and standard pharmacotherapy regimens for mild pneumonia (real practice). Subjects and Methods: An open-label comparative randomized trial was conducted in parallel groups of 147 patients aged > or = 18 years with mild CAP and risk factors for ineffective treatment. Group 1 included 61 patients (59 men and 2 women; mean age 23.3 +/- 11.2 years) receiving levofloxacin (Glevo) 500 mg/day; Group 2 comprised 41 patients (39 men and 1 woman; mean age 26.4 +/- 13.4 years) treated with original levofloxacin 500 mg/day; Group 3 consisted of 45 patients (all men; mean age 23.7 +/- 9.9 years) on standard therapy. The trial was performed in 3 pulmonology centers. Results: The use of the respiratory fluoroquinolone levofloxacinto treat mild CAP in the patients with risk factors for failure for its therapy demonstrated a higher efficiency than the antibiotic regimens used in real clinical practice. This suggests that physicians underestimate risk factors and do not always make a rational choice of an antimicrobial agent in the given clinical situation. Conclusion: The generic form of levofloxacin (Glevo) is as clinically effective as its original drug in the treatment of CAP and characterized by its optimal pharmacoeconomic parameters.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu